Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2020-10-13 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2020-10-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a distribution agreement between PharmaDrug's subsidiary Super Smart and Red Light Holland for iMicrodose Packs and the establishment of a media information center. It contains no financial data, no regulatory filings, no management or board changes, no voting results, no audit or earnings information, and no detailed financial or strategic presentation. It is a corporate announcement about a business partnership and operational update. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement or corporate news release that does not fit other specific categories.
2020-09-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a transaction for PharmaDrug Inc. acquiring a retail establishment in the Netherlands and outlining future expansion plans. It contains no financial statements, regulatory certifications, or detailed financial data. It is not an earnings release or annual/interim report. The content focuses on a business acquisition and strategic plans rather than merger filings or tender offers. It is a corporate announcement about a transaction closure and business strategy, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes through acquisition.
2020-09-21 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing employment agreements with executives, stock option grants, share-based compensation, and an update on the acquisition of a store. It includes details about insider transactions, related party transactions, and regulatory exemptions. There are no financial statements, quarterly or annual results, or detailed financial analysis. The content focuses on management agreements, stock option grants, and acquisition updates rather than financial results or regulatory filings. This fits best under Capital/Financing Update (CAP) because it involves stock option grants and share issuances related to financing and compensation, as well as acquisition progress updates. The document is not a full financial report, earnings release, or regulatory filing, nor is it a management or board change announcement exclusively. Therefore, the most appropriate classification is CAP with high confidence.
2020-09-01 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-08-27 English
Interim MD&A - English.pdf
Regulatory Filings
2020-08-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.